

**South America Human Papillomavirus (HPV) Vaccine Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Type (9-valent HPV Vaccine, Quadrivalent HPV Vaccine, and Bivalent HPV Vaccine), Dosage (2 Dose and 3 Dose), Age (9 to 14 Years and 15 to 45 Years), Application (HPV-Attributable Cancer and Genital Warts), and End User (Doctors Office, Community Health Clinics, School-Based Health Centers, Health Departments, Hospitals, and Others)**

Market Report | 2022-09-26 | 134 pages | The Insight Partners

**AVAILABLE LICENSES:**

- Single User Price \$3000.00
- Site Price \$4000.00
- Enterprise Price \$5000.00

**Report description:**

The South America human papillomavirus (HPV) vaccine market is expected to grow from US\$ 173.52 million in 2022 to US\$ 239.53 million by 2028; it is estimated to grow at a CAGR of 5.5% from 2022 to 2028.

Companies are undertaking many research and development activities to introduce advanced HPV tests. For instance, in May 2021, BD, a leading medical technology company, launched the first CE-marked assay for HPV screening from at-home self-collected vaginal samples. This allows laboratories to process self-collected samples via a BD diluent tube. At-home collection of samples will help address the urgent public health challenge of reaching out to women who do not attend routine cervical cancer screening. Further, in September 2020, drug administrations across the region approved the expanded use of F. Hoffmann-La Roche Ltd, CINTec PLUS Cytology, the first triage test based on biomarker technology for women whose cervical cancer screening results are positive for high-risk types of human papillomavirus (HPV). The CINTec PLUS Cytology test identifies the simultaneous presence of the two biomarkers-p16 and Ki-67-in a single cell. This abnormality is associated with HPV infections that progress to pre-cancer or cancer if not treated. A positive result of these two biomarkers means the person taking the test is at a high risk of getting the disease. Such robust developments in HPV diagnostics tests are likely to reshape the market during

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

the forecast period.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the South America human papillomavirus (HPV) vaccine market. The South America human papillomavirus (HPV) vaccine market is expected to grow at a good CAGR during the forecast period.

#### South America Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US\$ Million)

#### South America Human Papillomavirus (HPV) Vaccine Market Segmentation

The South America human papillomavirus (HPV) vaccine market is segmented based on type, dosage, age, application, end user, and country. Based on type, the South America human papillomavirus (HPV) vaccine market is segmented into 9-valent HPV vaccine, quadrivalent HPV vaccine, and bivalent HPV vaccine. The quadrivalent HPV vaccine segment would dominate the market in 2022. In terms of dosage, the South America human papillomavirus (HPV) vaccine market is bifurcated into 2 dose and 3 dose. The 2 dose segment would dominate the market in 2022. Based on age, the South America human papillomavirus (HPV) vaccine market is bifurcated into 9 to 14 years and 15 to 45 years. The 9 to 14 years segment would dominate the market in 2022. In terms of application, the South America human papillomavirus (HPV) vaccine market is bifurcated into HPV-attributable cancer and genital warts. The HPV-attributable cancer segment would dominate the market in 2022. Based on end user, the South America human papillomavirus (HPV) vaccine market is segmented into doctors office, community health clinics, school-based health centers, health departments, hospitals, and others. The hospitals segment would dominate the market in 2022. Based on country, the South America human papillomavirus (HPV) vaccine market has been categorized into Brazil, Argentina, Chile, Guatemala, Peru, Colombia, and the Rest of South America. Brazil would dominate the market in 2022.

GlaxoSmithKline plc.; Inovio Pharmaceuticals; Merck & Co., Inc.; R-Pharm; Sanofi; and Serum Institute of India Pvt. Ltd are among the leading companies in the South America human papillomavirus (HPV) vaccine market.

#### Table of Contents:

##### TABLE OF CONTENTS

- 1. Introduction
  - 1.1 Study Scope
  - 1.2 The Insight Partners Research Report Guidance
  - 1.3 Market Segmentation
    - 1.3.1 SAM Human Papillomavirus (HPV) Vaccines Market - By Type
    - 1.3.2 SAM Human Papillomavirus (HPV) Vaccines Market - By Dosage
    - 1.3.3 SAM Human Papillomavirus (HPV) Vaccines Market - By Age
    - 1.3.4 SAM Human Papillomavirus (HPV) Vaccines Market - By Application
    - 1.3.5 SAM Human Papillomavirus (HPV) Vaccines Market - By Distribution Channel
    - 1.3.6 SAM Human Papillomavirus (HPV) Vaccines Market - By Country
- 2. Key Takeaways
- 3. Research Methodology
  - 3.1 Coverage
  - 3.2 Secondary Research
  - 3.3 Primary Research
- 4. SAM Human Papillomavirus (HPV) Vaccine Market - Market Landscape
  - 4.1 Overview
  - 4.2 SAM PEST Analysis

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 4.3 Experts Opinion
- 5. SAM Human Papillomavirus (HPV) Vaccine Market - Key Market Dynamics
  - 5.1 Market Drivers
    - 5.1.1 Increase in Prevalence of HPV Associated Diseases
    - 5.1.2 Initiatives Taken by Health Organizations
  - 5.2 Market Restraints
    - 5.2.1 High Cost of HPV Vaccines
  - 5.3 Future Trends
    - 5.3.1 Advancements in HPV Diagnostics Tests
  - 5.4 Impact Analysis
- 6. Human Papillomavirus (HPV) Vaccine Market - SAM Analysis
  - 6.1 SAM Human Papillomavirus (HPV) Vaccine Market Revenue Forecast and Analysis
- 7. SAM Human Papillomavirus (HPV) Vaccine Market Analysis - By Type
  - 7.1 Overview
  - 7.2 By Type: Market Revenue and Forecast Analysis (US\$ Million)
  - 7.3 9-valent HPV vaccine
    - 7.3.1 Overview
    - 7.3.2 9-valent HPV vaccine Market Revenue and Forecast to 2028 (US\$ Million)
  - 7.4 Quadrivalent HPV vaccine
    - 7.4.1 Overview
    - 7.4.2 Quadrivalent HPV vaccine Market Revenue and Forecast to 2028 (US\$ Million)
  - 7.5 Bivalent HPV Vaccine
    - 7.5.1 Overview
    - 7.5.2 Bivalent HPV Vaccine Market Revenue and Forecast to 2028 (US\$ Million)
- 8. SAM Human Papillomavirus (HPV) Vaccine Market Analysis - By Dosage
  - 8.1 SAM Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Dosage (2022 and 2028)
  - 8.2 2 Dose
    - 8.2.1 Overview
    - 8.2.2 2 Dose: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US\$ Million)
  - 8.3 3 Dose
    - 8.3.1 Overview
    - 8.3.2 3 Dose: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US\$ Million)
- 9. SAM Human Papillomavirus (HPV) Vaccine Market Analysis - By Age
  - 9.1 SAM Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Age (2022 and 2028)
  - 9.2 9 to 14 Years
    - 9.2.1 Overview
    - 9.2.2 9 to 14 Years: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US\$ Million)
  - 9.3 to 45 Years
    - 9.3.1 Overview
    - 9.3.2 to 45 Years: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US\$ Million)
- 10. SAM Human Papillomavirus (HPV) Vaccine Market Analysis - By Application
  - 10.1 SAM Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Application (2022 and 2028)
  - 10.2 HPV-attributable Cancer
    - 10.2.1 Overview
    - 10.2.2 HPV-attributable Cancer: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US\$ Million)
  - 10.3 Genital Warts
    - 10.3.1 Overview

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 10.3.2 Genital Warts: Human Papillomavirus (HPV) Vaccine Market - Revenue and Forecast to 2028 (US\$ Million)
- 11. SAM Human Papillomavirus (HPV) Vaccine Market Analysis - By End User
  - 11.1 Overview
  - 11.2 SAM Human Papillomavirus (HPV) Vaccine Market Revenue Share, by End User (2022 and 2028)
  - 11.3 Doctor Office
    - 11.3.1 Overview
    - 11.3.2 Doctor Office Market Revenue and Forecast to 2028 (US\$ Million)
  - 11.4 Community Health Clinics
    - 11.4.1 Overview
    - 11.4.2 Community Health Clinics Market Revenue and Forecast to 2028 (US\$ Million)
  - 11.5 School-based Health Centers
    - 11.5.1 Overview
    - 11.5.2 School-based Health Centers Market Revenue and Forecast to 2028 (US\$ Million)
  - 11.6 Health Departments
    - 11.6.1 Overview
    - 11.6.2 Health Departments Market Revenue and Forecast to 2028 (US\$ Million)
  - 11.7 Hospitals
    - 11.7.1 Overview
    - 11.7.2 Hospitals Market Revenue and Forecast to 2028 (US\$ Million)
  - 11.8 Others
    - 11.8.1 Overview
    - 11.8.2 Others Market Revenue and Forecast to 2028 (US\$ Million)
- 12. SAM Human Papillomavirus (HPV) Vaccine Market - Country Analysis
  - 12.1 Overview
    - 12.1.1 SAM: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Country (%)
      - 12.1.1.1 Argentina Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US\$ Million)
        - 12.1.1.1.1 Overview
          - 12.1.1.1.2 Argentina: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028 (US\$ Million)
          - 12.1.1.1.3 Argentina: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Type (US\$ Million)
          - 12.1.1.1.4 Argentina: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Dosage (US\$ Million)
          - 12.1.1.1.5 Argentina: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Age (US\$ Million)
          - 12.1.1.1.6 Argentina: Human Papillomavirus (HPV) Vaccine Market, by Application - Revenue and Forecast to 2028 (US\$ Million)
          - 12.1.1.1.7 Argentina: Human Papillomavirus (HPV) Vaccine Market, by End User- Revenue and Forecast to 2028 (US\$ Million)
        - 12.1.1.1.2 Brazil: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US\$ Million)
          - 12.1.1.1.2.1 Overview
          - 12.1.1.1.2.2 Brazil: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028 (US\$ Million)
          - 12.1.1.1.2.3 Brazil: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Type (US\$ Million)
          - 12.1.1.1.2.4 Brazil: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Dosage (US\$ Million)
          - 12.1.1.1.2.5 Brazil: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Age (US\$ Million)
          - 12.1.1.1.2.6 Brazil: Human Papillomavirus (HPV) Vaccine Market, by Application - Revenue and Forecast to 2028 (US\$ Million)
          - 12.1.1.1.2.7 Brazil: Human Papillomavirus (HPV) Vaccine Market, by End User- Revenue and Forecast to 2028 (US\$ Million)
        - 12.1.1.1.3 Chile: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US\$ Million)
          - 12.1.1.1.3.1 Overview
          - 12.1.1.1.3.2 Chile: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028 (US\$ Million)
          - 12.1.1.1.3.3 Chile: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Type (US\$ Million)
          - 12.1.1.1.3.4 Chile: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Dosage (US\$ Million)
          - 12.1.1.1.3.5 Chile: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Age (US\$ Million)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 12.1.1.3.6 Chile: Human Papillomavirus (HPV) Vaccine Market, by Application - Revenue and Forecast to 2028 (US\$ Million)
- 12.1.1.3.7 Chile: Human Papillomavirus (HPV) Vaccine Market, by End User- Revenue and Forecast to 2028 (US\$ Million)
- 12.1.1.4 Guatemala: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US\$ Million)
  - 12.1.1.4.1 Overview
  - 12.1.1.4.2 Guatemala: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028 (US\$ Million)
  - 12.1.1.4.3 Guatemala: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Type (US\$ Million)
  - 12.1.1.4.4 Guatemala: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Dosage (US\$ Million)
  - 12.1.1.4.5 Guatemala: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Age (US\$ Million)
  - 12.1.1.4.6 Guatemala: Human Papillomavirus (HPV) Vaccine Market, by Application - Revenue and Forecast to 2028 (US\$ Million)
  - 12.1.1.4.7 Guatemala: Human Papillomavirus (HPV) Vaccine Market, by End User- Revenue and Forecast to 2028 (US\$ Million)
- 12.1.1.5 Peru: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US\$ Million)
  - 12.1.1.5.1 Overview
  - 12.1.1.5.2 Peru: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028 (US\$ Million)
  - 12.1.1.5.3 Peru: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Type (US\$ Million)
  - 12.1.1.5.4 Peru: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Dosage (US\$ Million)
  - 12.1.1.5.5 Peru: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Age (US\$ Million)
  - 12.1.1.5.6 Peru: Human Papillomavirus (HPV) Vaccine Market, by Application - Revenue and Forecast to 2028 (US\$ Million)
  - 12.1.1.5.7 Peru: Human Papillomavirus (HPV) Vaccine Market, by End User- Revenue and Forecast to 2028 (US\$ Million)
- 12.1.1.6 Colombia: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US\$ Million)
  - 12.1.1.6.1 Overview
  - 12.1.1.6.2 Colombia: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028 (US\$ Million)
  - 12.1.1.6.3 Colombia: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Type (US\$ Million)
  - 12.1.1.6.4 Colombia: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Dosage (US\$ Million)
  - 12.1.1.6.5 Colombia: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Age (US\$ Million)
  - 12.1.1.6.6 Colombia: Human Papillomavirus (HPV) Vaccine Market, by Application - Revenue and Forecast to 2028 (US\$ Million)
  - 12.1.1.6.7 Colombia: Human Papillomavirus (HPV) Vaccine Market, by End User- Revenue and Forecast to 2028 (US\$ Million)
- 12.1.1.7 Rest of South and Central America: Human Papillomavirus (HPV) Vaccine Market- Revenue and Forecast to 2028 (USD Million)
  - 12.1.1.7.1 Overview
  - 12.1.1.7.2 Rest of SAM: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028 (US\$ Million)
  - 12.1.1.7.3 Rest of SAM: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Type (US\$ Million)
  - 12.1.1.7.4 Rest of SAM: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Dosage (US\$ Million)
  - 12.1.1.7.5 Rest of SAM: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Age (US\$ Million)
  - 12.1.1.7.6 Rest of SAM: Human Papillomavirus (HPV) Vaccine Market, by Application - Revenue and Forecast to 2028 (US\$ Million)
  - 12.1.1.7.7 Rest of SAM: Human Papillomavirus (HPV) Vaccine Market, by End User- Revenue and Forecast to 2028 (US\$ Million)
- 13. Industry Landscape
  - 13.1 Overview
  - 13.2 Inorganic Growth Strategies
    - 13.2.1 Overview
  - 13.3 Organic Growth Strategies
    - 13.3.1 Overview
- 14. Company Profiles
  - 14.1 Merck & Co., Inc.
    - 14.1.1 Key Facts
    - 14.1.2 Business Description
    - 14.1.3 Products and Services
    - 14.1.4 Financial Overview

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
- 14.2 GlaxoSmithKline plc.
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
- 14.3 Serum Institute of India Pvt. Ltd
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
- 14.4 Inovio Pharmaceuticals
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
- 14.5 Sanofi
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
- 14.6 R-Pharm
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
- 15. Appendix
- 15.1 About The Insight Partners
- 15.2 Glossary of Terms

**South America Human Papillomavirus (HPV) Vaccine Market Forecast to 2028 -  
COVID-19 Impact and Regional Analysis - by Type (9-valent HPV Vaccine,  
Quadrivalent HPV Vaccine, and Bivalent HPV Vaccine), Dosage (2 Dose and 3 Dose),  
Age (9 to 14 Years and 15 to 45 Years), Application (HPV-Attributable Cancer and  
Genital Warts), and End User (Doctors Office, Community Health Clinics,  
School-Based Health Centers, Health Departments, Hospitals, and Others)**

Market Report | 2022-09-26 | 134 pages | The Insight Partners

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to [support@scotts-international.com](mailto:support@scotts-international.com)

**ORDER FORM:**

Select license	License	Price
	Single User Price	\$3000.00
	Site Price	\$4000.00
	Enterprise Price	\$5000.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact [support@scotts-international.com](mailto:support@scotts-international.com) or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-05"/>
		Signature	<input type="text"/>